Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288) - amlodipine 2.5 mg - amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program’s joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - amlodipine 5 mg - amlodipine and benazepril hydrochloride capsules, usp are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent. - do not coadminister aliskiren with angiotensin receptor blockers (arbs), ace inhibitors, including amlodipine and benazepril hydrochloride in patients with diabetes. - amlodipine and benazepril hydrochloride is contraindicated in patients with a history of angioedema, with or without previous ace inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ace inhibitor, to amlodipine, or to any of the excipients of amlodipine and benazepril hydrochloride capsules. - amlodipine and benazepril hydrochloride is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer amlodipine and benazepril hydrochloride capsules within 36 hours of switching to or from a neprilysin inhibitor, e.g., sacubitril/valsartan

Singapore - Tiếng Anh - HSA (Health Sciences Authority)

singapore pharmaceutical private limited - amlodipine besilate 6.94 mg equivalent to amlodipine - tablet - 5 mg - amlodipine besilate 6.94 mg equivalent to amlodipine 5 mg

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 80 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; crospovidone; hypromellose; purified talc; iron oxide yellow; macrogol 4000; titanium dioxide - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

les laboratoires servier - atorvastatin; perindopril arginine; amlodipine - film-coated tablet - 10 mg/5 mg/5 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz atorvastatin, amlodipine and perindopril - : lipid modifying agents, hmg coa reductase inhibitors, other combinations - triveram is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination.

Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

les laboratoires servier - atorvastatin; perindopril arginine; amlodipine - film-coated tablet - 20 mg/5 mg/5 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz atorvastatin, amlodipine and perindopril - : lipid modifying agents, hmg coa reductase inhibitors, other combinations - triveram is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination.

Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

les laboratoires servier - atorvastatin; perindopril arginine; amlodipine - film-coated tablet - 20 mg/10 mg/5 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz atorvastatin, amlodipine and perindopril - : lipid modifying agents, hmg coa reductase inhibitors, other combinations - triveram is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination.

Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

les laboratoires servier - atorvastatin; perindopril arginine; amlodipine - film-coated tablet - 20 mg/10 mg/10 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz atorvastatin, amlodipine and perindopril - lipid modifying agents, hmg coa reductase inhibitors, other combinations - triveram is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination

Ai-len - Tiếng Anh - HPRA (Health Products Regulatory Authority)

les laboratoires servier - atorvastatin; perindopril arginine; amlodipine - film-coated tablet - 40 mg/10 mg/10 milligram(s) - hmg coa reductase inhibitors, other combinations; zzz atorvastatin, amlodipine and perindopril - lipid modifying agents, hmg coa reductase inhibitors, other combinations - triveram is indicated for the treatment of essential hypertension and/or stable coronary artery disease, in association with primary hypercholesterolaemia or mixed hyperlipidaemia, as substitution therapy in adult patients adequately controlled with atorvastatin, perindopril and amlodipine given concurrently at the same dose level as in the combination.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

proficient rx lp - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - amlodipine 10 mg - amlodipine besylate and benazepril hydrochloride capsules, usp are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent.  pregnancy category d use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.  resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations.  potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.  when pregnancy is detected, discontinue amlodipine besylate and benazepril hydrochloride as soon as possible.  these adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy.  most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system fro